The content for this activity is based on the live, inter professional seminar titled, “The Emerging Role of CFTR Combination Regimens in Improving Outcomes for Patients With Cystic Fibrosis” that was presented at the 31^st Annual North American Cystic Fibrosis Conference in Indianapolis, Indiana. This CME/CNE activity will highlight the latest advances in CFTR-based therapeutics for the treatment of patients with cystic fibrosis. The expert faculty will utilize an interactive panel format to present and discuss recent trial data as it relates to clinical decision-making, including updates regarding the assessment, monitoring, and management of patients treated with CFTR modulated therapies. This educational activity is intended to increase the knowledge and competencies of the multidisciplinary team involved in the care of the CF patient population. Upon completion of this educational activity, the healthcare team will be better equipped with vital information for improving outcomes and quality of life in patients with cystic fibrosis.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with cystic fibrosis.

LEARNING OUTCOME STATEMENTS

At the conclusion of this activity:

KNOWLEDGE: Participants will self-report knowledge gained based on current best practices for improving outcomes and quality of life in patients with cystic fibrosis.

COMPETENCE/SKILL: Participants will self-report intent to change practice by applying current best practices for improving outcomes and quality of life in patients with cystic fibrosis.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

1. Review pathophysiology, genomic evaluation and functional implications of CF, including the underlying causing of disease to guide therapeutic selection
2. Examine clinical trial data of emerging combination therapies for the treatment of CF
3. Implement a data-driven and personalized CFTR modulated treatment plan to improve the life-long management of patients with CF

FACULTY

	John P. Clancy, MD (Chair) Professor of Pediatrics Director, Pulmonary Medicine Research Co- Director, CF Research Development Program Medical Director, Office of Clinical and Translational Research Gunnar Esiason/Cincinnati Bell Chair in Life Sciences Research Division of Pulmonary Medicine Cincinnati Children’s Hospital Medical Center Cincinnati, Ohio
	Jane Davies, MD Professor of Paediatric Respirology and Experimental Medicine Imperial College London Honorary Consultant in Paediatric Respiratory Medicine Royal Brompton and Harefield NHS Foundation Trust London, United Kingdom
	Carlos Milla, MD Professor and Director The Stanford Cystic Fibrosis Center Associate Director for Translational Research Center for Excellence in Pulmonary Biology Stanford University Palo Alto, California
	Kristin A. Riekert, PhD Associate Professor Director, Johns Hopkins Adherence Research Center Director, Cystic Fibrosis Adherence Program Johns Hopkins School of Medicine Baltimore, Maryland
	Gregory Sawicki, MD, MPH Director, Cystic Fibrosis Center Boston Children's Hospital Assistant Professor of Pediatrics Harvard Medical School Boston, Massachusetts
	Jennifer L. Taylor-Cousar, MD, MSCS Medical Director, Clinical Research Services Co-Director and CF TDN Director, Adult CF Program Associate Professor, Departments of Medicine and Pediatrics Divisions of Pulmonary, Critical Care and Sleep Medicine and Pediatric Pulmonary Medicine Denver, Colorado

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education and Elsevier that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Financial Support

This activity has been supported by an independent educational grant from Vertex Pharmaceuticals Incorporated.

PROVIDER INFORMATION

Provided in collaboration with the Elsevier Office of Continuing Medical Education, Elsevier and AcademicCME.

CME CREDIT (PHYSICIANS)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE CREDIT (NURSES)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of EOCME, Elsevier, and AcademicCME. EOCME is accredited by the ACCME to provide continuing medical education for physicians.

CME/CNE INQUIRIES/SPECIAL NEEDS

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Elsevier, AcademicCME and Vertex Pharmaceuticals Incorporated do not recommend the use of any agent outside of the labeled indications.  

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.